Molecular activators of the wnt/beta-catenin pathway

Abstract

The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

What is claimed: 
     
         1 . A method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling, said method comprising:
 selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and 
 administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. 
 
     
     
         2 . The method of  claim 1 , wherein the subject is human. 
     
     
         3 . The method of  claim 1 , wherein a compound of Table 1 or a pharmaceutically acceptable salt thereof is administered. 
     
     
         4 . The method of  claim 1 , wherein a compound of Table 2 or a pharmaceutically acceptable salt thereof is administered. 
     
     
         5 . The method of  claim 1 , wherein the condition is selected from the group consisting of cancer, bone mass diseases, fracture repair, FEVR, diabetes mellitus, cord blood transplants, psychiatric disease, neurodegenerative disease, hair loss, diseases linked to loss of stem/progenitor cells, conditions improved by increasing stem/progenitor cell populations, HIV, and tooth agenesis. 
     
     
         6 . A method of activating the Wnt/β-catenin pathway in a subject comprising:
 selecting a subject in need of Wnt/β-catenin pathway activating and 
 administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. 
 
     
     
         7 . The method of  claim 6 , wherein a compound of Table 1 or a pharmaceutically acceptable salt thereof is administered. 
     
     
         8 . The method of  claim 6 , wherein a compound of Table 2 or a pharmaceutically acceptable salt thereof is administered.